Marriott Eloise, Singanayagam Aran, El-Awaisi Juma
Microcirculation Research Group, Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.
MRC Centre for Molecular Bacteriology & Infection, Department of Infectious Disease, Imperial College London, London, United Kingdom.
Front Cardiovasc Med. 2024 Feb 21;11:1362564. doi: 10.3389/fcvm.2024.1362564. eCollection 2024.
Chronic obstructive pulmonary disease (COPD), particularly following acute exacerbations (AE-COPD), significantly heightens the risks and mortality associated with acute myocardial infarction (AMI). The intersection of COPD and AMI is characterised by a considerable overlap in inflammatory mechanisms, which play a crucial role in the development of both conditions. Although extensive research has been conducted on individual inflammatory pathways in AMI and COPD, the understanding of thrombo-inflammatory crosstalk in comorbid settings remains limited. The effectiveness of various inflammatory components in reducing AMI infarct size or slowing COPD progression has shown promise, yet their efficacy in the context of comorbidity with COPD and AMI is not established. This review focuses on the critical importance of both local and systemic inflammation, highlighting it as a key pathophysiological connection between AMI and COPD/AE-COPD.
慢性阻塞性肺疾病（COPD），尤其是在急性加重期（AE-COPD）之后，会显著增加与急性心肌梗死（AMI）相关的风险和死亡率。COPD和AMI的交叉点在于炎症机制存在相当大的重叠，这在两种疾病的发展中都起着关键作用。尽管已经对AMI和COPD中的个体炎症途径进行了广泛研究，但对合并症情况下血栓炎症相互作用的理解仍然有限。各种炎症成分在减少AMI梗死面积或减缓COPD进展方面已显示出前景，但其在COPD和AMI合并症背景下的疗效尚未确定。本综述重点关注局部和全身炎症的至关重要性，强调其作为AMI与COPD/AE-COPD之间关键病理生理联系的地位。
